Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to three branded targeted therapies. With a large unmet clinical need, further agents are required to increase survival and delay disease progression. Unique breast cancer market share, sales forecasts by launched and Phase III products to 2017 A comprehensive and critical examination and scoring of 72 major breast cancer treatments Comprehensive market assessment of therapeutic approaches, company share, portfolios and prospects Breast Cancer Therapy Sales Forecast 2010-2017 'What's the story behind this chart?' The changing competitive landscape By 2017, Espicom forecasts a modest increase in the number of players in the market-place compared to 2010, with Roche, and GlaxoSmithKline to a lesser extent, triumphing with targeted therapies directed against the specific subset of BC patients with HER2-positive disease. AstraZeneca, Novartis and Pfizer will face widespread generic competition for their hormonal therapies, leading to a loss of market share. Similarly, Sanofi and Eli Lilly will face declining sales for their chemotherapies. The market in 2010... In recent years, more effective treatments have decreased mortality and improved survival rates, resulting in a longer duration of therapy for an increased patient population. In the US, five-year relative survival rates have improved from 63% in the early 1960s to 90% in recent years, while in England, rates for women diagnosed with BC in 2001-2006 reached 82%, compared to 52% 1971-1975. This report estimates that sales of leading brands achieved sales of US$12.7 billion in 2010, with growth due to expanding sales for a number of existing treatments rather than the launch of new products. Sales were split between chemotherapies, hormonal therapies and novel molecular targeted therapies, with the majority of these agents used in combination. And 2017: how things might change Hormonal therapies The aromatase inhibitors will suffer from patent expiries in all major markets by 2012, and the report expects significant generic competition and sales for this group to decline by over 92% from US$3.4 billion in 2010, to just US$259 million in 2017. With widespread generic versions of the leading selective oestrogen receptor modulator, tamoxifen, the overall market share of branded hormonal therapies will decline as sales fall from US$4 billion to US$1.4 billion, a drop of 65%. These declines will be tempered by the relative success of AstraZeneca's Faslodex. Chemotherapies By 2017, most chemotherapies will be available as generics. In addition to patent expirations for Sanofi's Taxotere (docetaxel) and Eli Lilly's Gemzar (gemcitabine) in 2009/2010, the US patent on Roche's Xeloda (capecitabine) will expire in 2013. As a direct result, sales will decrease by almost 40% from over US$2.4 billion in 2010 to around US$1.5 billion in 2017, with market share continuing to decline, from 19 to 12%. This general trend is mitigated somewhat by the newer chemotherapies, which are demonstrating sales growth and carving out market share due to their improved safety and efficacy compared to older more established agents. Targeted therapies moving beyond HER2 - By 2017, Espicom estimates that a total of ten products will command a 77% market share, with the current therapies, Roche's Herceptin and Avastin, along with GSK's Tykerb/Tyverb, accounting for over 80% of these sales. Herceptin will continue as the clear market leader. But what about patients who are HER2 negative?
There is an urgent need for more therapies and just a handful are likely to be launched by 2017: - Bayer's Nexavar is a multi-targeted kinase inhibitor already marketed for the treatment of renal cell carcinoma and hepatocellular carcinoma. Eli Lilly's anti-vegfr2 monoclonal antibody, ramucirumab, an angiogenesisinhibitor, may be able to pick up market share from Avastin if the company can demonstrate an improved survival advantage. - There has been considerable optimism over a novel class of agents, the PARP inhibitors, including Sanofi's iniparib, which is under development for triplenegative breast cancer. Nevertheless, doubt has been cast over the effectiveness of this class following the termination of the development of AstraZeneca's olaparib. About the Author: This report has been written by Sue Viney, a senior writer on Espicom's oncology analysis team. Sue has been evaluating companies, products and drugs in research for 12 years. She is editor of Cancer Drug Futures and, in addition, has also produced management reports on the lung, colorectal, prostate and renal cancer areas as well as studies on Rheumatoid Arthritis and CNS drug development. Ordering: Order Online - http://www.researchandmarkets.com/reports/679630/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8,
Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Breast Cancer Drug Discoveries: What the Future Holds http://www.researchandmarkets.com/reports/679630/ SC Product Formats Please select the product formats and quantity you require: Electronic (PDF) - Single User: Electronic (Online Access) - Single User: Electronic (PDF) - Enterprisewide: Electronic (Online Access) - Enterprisewide: Quantity USD 2518 USD 2518 USD 15106 USD 15106 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Page 1 of 2
Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code IBAN number Bank Address ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World